KRAS and non-small cell lung carcinoma: Results indicated that the efficacy of PTX was decreased when KRAS and RAF1 were overexpressed in ALDH2 knockdown NSCLC/PTX cells (Fig. 5E-F), and the effect was similar to that observed when ALDH2 expression was rescued (Fig. S6D).